New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
10:15 EDTINSMInsmed drops, bounces, after Arikayce Phase 2 trial results
The stock is down over 10% at time of writing to $16.46 after Arikayce did not achieve the primary endpoint in Phase 2 trial. Shares hit a low of $15.69, currently support, and then bounced. Resistance is at the session high at $17.38. Piper Jaffray noted that the 'much more meaningful' secondary endpoint was met.
News For INSM From The Last 14 Days
Check below for free stories on INSM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 12, 2014
19:27 EDTINSMInsmed 8.9M share Secondary priced at $11.25
Leerink acted as sole book running manager for the offering.
August 11, 2014
17:26 EDTINSMPoint72 Asset reports 5.4% passive stake in Insmed
Subscribe for More Information
16:40 EDTINSMInsmed files to sell $80M of common stock
Subscribe for More Information
August 8, 2014
10:34 EDTINSMOptions with decreasing implied volatility
Subscribe for More Information
August 7, 2014
10:28 EDTINSMOptions with decreasing implied volatility
Subscribe for More Information
August 6, 2014
10:59 EDTINSMOptions with decreasing implied volatility
Subscribe for More Information
07:36 EDTINSMInsmed reports Q2 EPS (59c), consensus (46c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use